ASCO A Focus On Leukemia eBook
ASCO Leukemia 2022.indd
Jan 10, 2022
According to published data, patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) experience frequent relapses over the course of...
Jan 10, 2022
The establishment of ibrutinib as a preferred first-line treatment option makes it important to understand the treatment sequence following first-line ibrutinib and the patient characteristics of those treated with a second-line...
Jan 10, 2022
Currently, the effect of the diagnosis-to-treatment interval (DTI) on survival in patients with mantle cell lymphoma (MCL) has not been extensively examined. Researchers aimed to determine the feasibility of active surveillance...
Jan 8, 2022
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...